Sa'ar Yaniv, Research Analyst
t: 646-358-1906, e: email@example.com
Sa'ar Yaniv is a Research Analyst covering Biotechnology companies. He joined ROTH Capital Partners in April 2016, and his research focuses on metabolic diseases, including diabetes, obesity, NASH, lipidemia, and liver and rare diseases. Mr. Yaniv brings over 10 years of experience to the firm. He previously worked at Oppenheimer and JPMorgan in Biotechnology equity research, before starting a consulting firm, where he specialized in valuation and competitive intelligence for Biotechnology companies. He re-joined sell-side equity research in 2015 at Oppenheimer. Mr. Yaniv earned his B.S. in Biochemistry from University of California, Davis.